T. Facon Et Al. , "Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis," HEMATOLOGICAL ONCOLOGY , vol.40, no.5, pp.1020-1029, 2022
Facon, T. Et Al. 2022. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. HEMATOLOGICAL ONCOLOGY , vol.40, no.5 , 1020-1029.
Facon, T., Moreau, P., Martin, T. G., Spicka, I., Oriol, A., Koh, Y., ... Lim, A.(2022). Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. HEMATOLOGICAL ONCOLOGY , vol.40, no.5, 1020-1029.
Facon, Thierry Et Al. "Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis," HEMATOLOGICAL ONCOLOGY , vol.40, no.5, 1020-1029, 2022
Facon, Thierry Et Al. "Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis." HEMATOLOGICAL ONCOLOGY , vol.40, no.5, pp.1020-1029, 2022
Facon, T. Et Al. (2022) . "Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis." HEMATOLOGICAL ONCOLOGY , vol.40, no.5, pp.1020-1029.
@article{article, author={Thierry Facon Et Al. }, title={Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis}, journal={HEMATOLOGICAL ONCOLOGY}, year=2022, pages={1020-1029} }